Hyperprolactinemia: etiology, diagnosis, and management

Semin Reprod Med. 2002 Nov;20(4):365-74. doi: 10.1055/s-2002-36709.

Abstract

Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis. A prolactinoma is the most common cause of chronic hyperprolactinemia once pregnancy, primary hypothyroidism, and drugs that elevate serum prolactin levels have been excluded. Patients can present with hypogonadism, infertility, galactorrhea, osteopenia, and mass effects of the tumor. When hyperprolactinemia is confirmed, a cause for the disorder needs to be sought. This involves a careful history and examination, followed by laboratory tests and diagnostic imaging of the sella turcica. The goals of treatment are to normalize prolactin levels, restore gonadal function, and reduce the effects of chronic hyperprolactinemia. Dopamine agonists are the treatment of choice for the majority of patients. Transsphenoidal surgery is usually reserved for patients who are intolerant of or resistant to dopamine agonists or when hyperprolactinemia is caused by non-prolactin-secreting tumors compressing the pituitary stalk. Cabergoline has been shown to be more effective and better tolerated than bromocriptine. However, there are more data on the safety of the latter drug during pregnancy and bromocriptine, therefore, remains the treatment of choice in hyperprolactinemic women wishing to conceive.

Publication types

  • Review

MeSH terms

  • Bromocriptine / therapeutic use
  • Cabergoline
  • Dopamine Agonists / therapeutic use
  • Ergolines / therapeutic use
  • Humans
  • Hyperprolactinemia / diagnosis*
  • Hyperprolactinemia / epidemiology
  • Hyperprolactinemia / etiology
  • Hyperprolactinemia / therapy*
  • Neurosurgical Procedures
  • Prevalence

Substances

  • Dopamine Agonists
  • Ergolines
  • Bromocriptine
  • Cabergoline